SCHEMBL5566622

SCHEMBL5566622

Cn1ccnc1C(O)(c1ccc(Cl)cc1)c1ccc([N+](=O)[O-])cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
LMNA P02545 4/20 0.41
ALDH1A1 P00352 6/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HSD11B1 P28845 1/20 0.38
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
HSD17B10 Q99714 1/20 0.36
MAPT P10636 3/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NPC1 O15118 2/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046727 0.88 KMT2A (0.51) KMT2ALMNAALDH1A1FNTAFNTB
SCHEMBL11534295 0.77 KMT2A (0.66) KMT2AALDH1A1RAB9ASMN1; SMN2MEN1
SCHEMBL5560368 0.75 CYP19A1 (0.63) KMT2ASMN1; SMN2MAPTMEN1CYP3A4
SCHEMBL11531547 0.72 KMT2A (0.77) KMT2AMEN1CYP3A4
SCHEMBL11858453 0.72 HSD17B10 (0.51) KMT2ALMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL4055564 0.71 KMT2A (0.57) KMT2AALDH1A1RAB9ASMN1; SMN2MEN1
SCHEMBL8243325 0.71 KMT2A (0.57) KMT2AALDH1A1RAB9ASMN1; SMN2MEN1
SCHEMBL5705666 0.69 KMT2A (0.43) KMT2ALMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL4905689 0.68 KMT2A (0.53) KMT2AALDH1A1RAB9ASMN1; SMN2MEN1
SCHEMBL4054111 0.67 FNTA (0.59) FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000040-B1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2005-04-28 US disclosed
US-6867207-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-15 US disclosed
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2004-08-26 US disclosed
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives LACRAMPE JEAN FERNAND ARMAND (FR) 2002-06-13 US disclosed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 EP disclosed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs IL6ST, CXCR5, ALOX5 KMT2A 4336/4885LMNA 4455/4885ALDH1A1 1219/4885
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs CXCR5, HCAR3, IL6ST KMT2A 4590/4885LMNA 4686/4885ALDH1A1 1331/4885
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives IL6ST, ALOX5, IL5 KMT2A 3274/4885LMNA 3842/4885ALDH1A1 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.